Stafloxin 200

Stafloxin 200 contains ofloxacin, a quinolone-carboxylic acid derivative with a wide range of antibacterial activity against both gram-negative and gram-positive organisms. Stafloxin 200 is indicated for treatments of the following infections when caused by sensitive organisms.

Pack size Box of 10 tablets, 20 tablets, 100 tablets. Bottle of 100 tablets.
Shelf-life 48 months
Composition Ofloxacin
Dosage forms and strengths Film-coated tablet: 200 mg
Product code :



  • Prostatitis.
  • Uncomplicated urethral and cervical gonorrhoea.
  • Non – gonococcal urethritis and cervicitis.
  • Skin and soft tissue infections.
  • Lower urinary tract infection.
  • Upper urinary tract infection.
  • Acute bacterial exacerbations of chronic bronchitis.
  • Impaired renal function.


  • Prostatitis: 300 mg every 12 hours for 6 weeks.
  • Uncomplicated urethral and cervical gonorrhoea: A single dose of 400 mg.
  • Non – gonococcal urethritis and cervicitis: 400 mg daily in single or divided doses.
  • Skin and soft tissue infections: 400 mg twice daily.
  • Lower urinary tract infection: 200 – 400 mg daily.
  • Upper urinary tract infection: 200 – 400 mg daily increasing, if necessary, to 400 mg twice a day.
  • Acute bacterial exacerbations of chronic bronchitis: 400 mg daily increasing, if necessary, to 400 mg twice daily.
  • Impaired renal function: Following a normal initial dose, dosage should be reduced in patients with impairment of renal function.
  • The usual treatment period is 5 – 10 days except in uncomplicated gonorrhoea, where a single dose is recommended. Treatment should not exceed 2 months duration.


Stafloxin 200 is administered orally, preferably in the morning.

In patients hypersensitive to ofloxacin or other quinolones or any of the excipients.

Patients with a past history of tendinitis.

Patients with a history of epilepsy or with a lowered seizure threshold.

Children or growing adolescents, and in pregnant or breast-feeding women.

Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity.

Disabling and potentially irreversible serious adverse reactions including tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects.

Common: Nausea, vomiting, diarrhoea, abdominal pain; headache, dizziness, restlessness, tremor, drowsiness, insomnia, bad dreams and visual disturbances; rash, pruritus, hypersensitivity type reactions affecting the skin.

Avoid the use of fluoroquinolones in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones. Discontinue this medicine immediately at the first signs or symptoms of any serious adverse reactions.

Treatment with ofloxacin must be halted immediately if:

  • There are first signs of hypersensitivity reactions.
  • Patients experience pain, inflammation, or rupture of a tendon. Rest and refrain from exercise until a diagnosis of tendinitis or tendon rupture is excluded.

Extreme caution should be exercised when use ofloxacin for:

  • Patients with renal impairment.
  • Patients with a history of psychotic disorder or in patients with psychiatric disease.

The patient’s condition must therefore be check at regular intervals. If a secondary infection occurs, appropriate measures must be taken.

Patients should be aware of how they react to drug before driving or operating machinery. Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient’s ability to concentrate and react.